In various settings, primarily in the context of immunomodulation and the treatment of autoimmune diseases, the dual inhibition of APN/CD13 and of the ectopeptidase DPP4/CD26 has been shown to be more effective than the inhibition of APN/CD13 alone. The gene discussed is DPP4; the disease is autoimmune disease.